Dried blood spot IP-10 as a biomarker of tuberculosis severity and treatment responses: results from a phase IIb trial of adjunctive acetylsalicylic acid and ibuprofen.
- DOI
- 10.3389/fimmu.2026.1924239
- Published
- 2026
- Container
- Frontiers in immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fimmu.2026.1924239,
title = {Dried blood spot IP-10 as a biomarker of tuberculosis severity and treatment responses: results from a phase IIb trial of adjunctive acetylsalicylic acid and ibuprofen.},
author = {Høgbakk Edlund I and Alonso-Rodriguez N and Sopegno C and Farrés J and Gogichadze N and Arias L and Fonseca KL and Otwombe K and Waja Z and Moloantoa T and Pillay N and Seiphetlo T and Martinson N and Vilaplana C and Dyrhol-Riise AM},
year = {2026},
journal = {Frontiers in immunology},
doi = {10.3389/fimmu.2026.1924239},
url = {https://doi.org/10.3389/fimmu.2026.1924239}
}RIS
TY - JOUR TI - Dried blood spot IP-10 as a biomarker of tuberculosis severity and treatment responses: results from a phase IIb trial of adjunctive acetylsalicylic acid and ibuprofen. AU - Høgbakk Edlund I AU - Alonso-Rodriguez N AU - Sopegno C AU - Farrés J AU - Gogichadze N AU - Arias L AU - Fonseca KL AU - Otwombe K AU - Waja Z AU - Moloantoa T AU - Pillay N AU - Seiphetlo T AU - Martinson N AU - Vilaplana C AU - Dyrhol-Riise AM PY - 2026 JO - Frontiers in immunology DO - 10.3389/fimmu.2026.1924239 UR - https://doi.org/10.3389/fimmu.2026.1924239 ER -
APA
I, H. E., N, A., C, S., J, F., N, G., L, A., KL, F., K, O., Z, W., T, M., N, P., T, S., N, M., C, V., & AM, D. (2026). Dried blood spot IP-10 as a biomarker of tuberculosis severity and treatment responses: results from a phase IIb trial of adjunctive acetylsalicylic acid and ibuprofen.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1924239
Source records
- pubmed · retrieved 2026-11-10T13:03:04.157Z